M. Scott Maguire-CEO/co-founder of Wellford Medical and Cannaray with 35 years’ experience of building and managing early stage Life Sciences & Healthcare companies through to IPO and trade sale in the U.S. and the U.K. MBA in finance and BA in biochemistry.
Co-Founder (Director) Renal Services, London
· Co-Founded this start-up business, acquiring a small loss-making holiday dialysis clinic.
· Led the acquisition to commence Renal Services operations and raised capital from individuals.
· Raised private capital and GBP£3m of Private Equity from Business Growth Fund (BGF).
· The Company was the second largest private provider of dialysis services in the UK with 26 clinics treating over 2,500 patients before being sold to DaVita Inc. PE Group, BGF, realised one of the highest returns on investment to date.
Chairman/Chief Executive Officer Xenetic Biosciences Inc., London/Boston (NASDAQ: XBIO listed).
· Led listing on NASDAQ in 2016
· Successfully raised circa US$100m in the public markets.
· Evolved the business from start-up to Phase 2 clinical candidates focused on orphan and rare blood diseases.
· Originated and negotiated all license and research deals with clients including Baxter, a US$150m license deal
· Identified and secured a range of key global biotech strategic investors including Serum Institute of India (US$5m) and Baxter/Shire (US$13m).
· Relocated Company from London to Boston, MA in 2010.